The molecular basis of Clostridium difficile disease and host response

Current Opinion in Gastroenterology

Volumn 31, Issue 1, 2015, Pages 24-29

  El Feghaly, Rana E ^a   Bangar, Hansraj ^b   Haslam, David B ^b  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Biomarkers; Clostridium difficile; Host response; Inflammatory cytokines; Intestinal inflammation

Indexed keywords

C REACTIVE PROTEIN; FIDAXOMICIN; INTERLEUKIN 8; METRONIDAZOLE; VANCOMYCIN; BIOLOGICAL MARKER;

ANTIBIOTIC THERAPY; ASYMPTOMATIC INFECTION; BACTERIAL TRANSMISSION; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COMMENSAL; DIARRHEA; DISEASE SEVERITY; ENTERITIS; FECAL MICROBIOTA TRANSPLANTATION; FECES MICROFLORA; HUMAN; IMMUNE RESPONSE; INFECTION SENSITIVITY; INTESTINE FLORA; NEUTROPHIL COUNT; NONHUMAN; PATHOGENESIS; RECURRENT INFECTION; REVIEW; TRANSPLANTATION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; GENETICS; HOST PATHOGEN INTERACTION; METABOLISM; MICROBIOLOGY; MICROFLORA; PATHOGENICITY; PEPTOCLOSTRIDIUM DIFFICILE; PHYSIOLOGY; PROCEDURES; TISSUE TRANSPLANTATION;

BIOLOGICAL MARKERS; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; HOST-PATHOGEN INTERACTIONS; HUMANS; MICROBIOTA; TISSUE TRANSPLANTATION;

EID: 84917682907     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000131     Document Type: Review

References (57)

1. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002; 346:334-339.
2. McFarland LV. Update on the changing epidemiology of Clostridium difficileassociated disease. Nat Clin Pract Gastroenterol Hepatol 2008; 5:40-48.
3. Benson L, Song X, Campos J, Singh N. Changing epidemiology of Clostridium difficile-associated disease in children. Infect Control Hosp Epidemiol 2007; 28:1233-1235.
4. Khanna S, Baddour LM, Huskins WC, et al. The epidemiology of Clostridium difficile infection in children: a population-based study. Clin Infect Dis 2013; 56:1401-1406.
5. Alasmari F, Seiler SM, Hink T, et al. Prevalence and risk factors for asymptomatic Clostridium difficile carriage. Clin Infect Dis 2014; 59:216-222.
6. Eyre DW, Cule ML, Wilson DJ, et al. Diverse sources of C. difficile infection identified on whole-genome sequencing. N Engl J Med 2013; 369:1195-1205.
7. Brabazon E, Carton M, Sheehan R, et al. Diversity in prevalent PCR ribotypes of clinical strains of C. difficile. Ir Med J 2014; 107:16-18.
8. Lim SK, Stuart RL, Mackin KE, et al. Emergence of a ribotype 244 strain of Clostridium difficile associated with severe disease and related to the epidemic ribotype 027 strain. Clin Infect Dis 2014; 58:1723-1730.
9. Healthcare Associated Infection Consortium. Tickler IA, Goering RV, Whitmore JD, et al. Strain types and antimicrobial resistance patterns of Clostridium difficile isolates from the United States: 2011-2013. Antimicrob Agents Chemother 2014; 58:4214-4218.
10. See I, Mu Y, Cohen J, et al. NAP1 strain type predicts outcomes from Clostridium difficile infection. Clin Infect Dis 2014; 58:1394-1400.
11. Cohen J, Limbago B, Dumyati G, et al. Impact of changes in Clostridium difficile testing practices on stool rejection policies and C. difficile positivity rates across multiple laboratories in the United States. J Clin Microbiol 2014; 52:632-634.
12. Moehring RW, Lofgren ET, Anderson DJ. Impact of change to molecular testing for Clostridium difficile infection on healthcare facility-associated incidence rates. Infect Control Hosp Epidemiol 2013; 34:1055-1061.
13. Fuentes S, van Nood E, Tims S, et al. Reset of a critically disturbed microbial ecosystem: faecal transplant in recurrent Clostridium difficile infection. ISME J 2014; 8:1621-1633.
14. Kelly CR, Ihunnah C, Fischer M, et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol 2014; 109:1065-1071.
15. Pierog A, Mencin A, Reilly NR. Fecal microbiota transplantation in children with recurrent Clostridium difficile infection. Pediatr Infect Dis J 2014. [Epub ahead of print]
16. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368:407-415.
17. Galdys AL, Curry SR, Harrison LH. Asymptomatic Clostridium difficile colonization as a reservoir for Clostridium difficile infection. Expert Rev Anti Infect Ther 2014; 12:967-980.
18. Lucado J, Gould C, Elixhauser A. Clostridium Difficile infections (CDI) in hospital stays, 2009: statistical brief #124. In Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Edited by the Agency for Healthcare Policy and Research (US); 2009.
19. Society for Healthcare Epidemiology of America, Infectious Diseases Society of America. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431-455.
20. Saujet L, Pereira FC, Serrano M, et al. Genome-wide analysis of cell typespecific gene transcription during spore formation in Clostridium difficile. PLoS Genet 2013; 9:e1003756.
21. Pereira FC, Saujet L, Tome AR, et al. The spore differentiation pathway in the enteric pathogen Clostridium difficile. PLoS Genet 2013; 9:e1003782.
22. Adams CM, Eckenroth BE, Putnam EE, et al. Structural and functional analysis of the CspB protease required for Clostridium spore germination. PLoS Pathog 2013; 9:e1003165.
23. Jank T, Giesemann T, Aktories K. Rho-glucosylating Clostridium difficile toxins A and B: new insights into structure and function. Glycobiology 2007; 17:15R-22R.
24. Hundsberger T, Braun V, Weidmann M, et al. Transcription analysis of the genes tcdA-E of the pathogenicity locus of Clostridium difficile. Eur J Biochem 1997; 244:735-742.
25. Dingle KE, Elliott B, Robinson E, et al. Evolutionary history of the Clostridium difficile pathogenicity locus. Genome Biol Evol 2014; 6:36-52.
26. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin genevariant strain of Clostridium difficile. N Engl J Med 2005; 353:2433-2441.
27. Aktories K, Barbieri JT. Bacterial cytotoxins: targeting eukaryotic switches. Nat Rev Microbiol 2005; 3:397-410.
28. Bobo LD, El Feghaly RE, Chen YS, et al. MAPK-activated protein kinase 2 contributes to Clostridium difficile-associated inflammation. Infect Immun 2013; 81:713-722.
29. Xu H, Yang J, Gao W, et al. Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome. Nature 2014; 513:237-241.
30. Walker AS, Eyre DW, Wyllie DH, et al. Relationship between bacterial strain type, host biomarkers and mortality in Clostridium difficile infection. Clin Infect Dis 2013; 56:1589-1600.
31. Khanafer N, Toure A, Chambrier C, et al. Predictors of Clostridium difficile infection severity in patients hospitalised in medical intensive care. World J Gastroenterol 2013; 19:8034-8041.
32. Rao K, Walk ST, Micic D, et al. Procalcitonin levels associate with severity of Clostridium difficile infection. PLoS One 2013; 8:e58265.
33. Chen K, d'Arc S, Setty N, et al. In recurrent C. difficile, the CRP response to the primary C. difficile infection predicts whether the same strain or a different strain will cause a second infection. Dig Dis Sci 2013; 58:1683-1688.
34. Lavergne V, Beausejour Y, PichetteG, et al. Lymphopenia as a novel marker of Clostridium difficile infection recurrence. J Infect 2013; 66:129-135.
35. Bloomfield MG, Carmichael AJ, Gkrania-Klotsas E. Mortality in Clostridium difficile infection: a prospective analysis of risk predictors. Eur J Gastroenterol Hepatol 2013; 25:700-705.
36. Kumarappa VS, Patel H, Shah A, et al. Temporal changes in serum albumin and total protein in patients with hospital-acquired Clostridium difficile infection. Ann Clin Lab Sci 2014; 44:32-37.
37. Rao K, Erb-Downward JR, Walk ST, et al. The systemic inflammatory response to Clostridium difficile infection. PLoS One 2014; 9:e92578.
38. Yacyshyn MB, Reddy TN, Plageman LR, et al. Clostridium difficile recurrence is characterized by pro-inflammatory peripheral blood mononuclear cell (PBMC) phenotype. J Med Microbiol 2014; 63:1260-1273.
39. Steiner TS, Flores CA, Pizarro TT, Guerrant RL. Fecal lactoferrin, interleukin- 1beta, and interleukin-8 are elevated in patients with severe Clostridium difficile colitis. Clin Diagn Lab Immunol 1997; 4:719-722.
40. Wren MW, Kinson R, Sivapalan M, et al. Detection of Clostridium difficile infection: a suggested laboratory diagnostic algorithm. Br J Biomed Sci 2009; 66:175-179.
41. Boone JH, DiPersio JR, Tan MJ, et al. Elevated lactoferrin is associated with moderate to severe Clostridium difficile disease, stool toxin, and 027 infection. Eur J Clin Microbiol Infect Dis 2013; 32:1517-1523.
42. Boone JH, Archbald-Pannone LR, Wickham KN, et al. Ribotype 027 Clostridium difficile infections with measurable stool toxin have increased lactoferrin and are associated with a higher mortality. Eur J Clin Microbiol Infect Dis 2014; 33:1045-1051.
43. Darkoh C, Turnwald BP, Koo HL, et al. Colonic immunopathogenesis of Clostridium difficile infections. Clin Vaccine Immunol 2014; 21:509-517.
44. Buonomo EL, Madan R, Pramoonjago P, et al. Role of interleukin 23 signaling in Clostridium difficile colitis. J Infect Dis 2013; 208:917-920.
45. El Feghaly RE, Stauber JL, Deych E, et al. Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection. Clin Infect Dis 2013; 56:1713-1721.
46. El Feghaly RE, Stauber JL, Tarr PI, Haslam DB. Intestinal inflammatory biomarkers and outcome in pediatric Clostridium difficile infections. J Pediatr 2013; 163:1697-1704.
47. Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005; 40:1586-1590.
48. Nelson RL, Kelsey P, Leeman H, et al. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 2011; CD004610.
49. Vardakas KZ, Polyzos KA, Patouni K, et al. Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. Int J Antimicrob Agents 2012; 40:1-8.
50. OPT-80-003 Clinical Study Group. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364:422-431.
51. Kinnebrew MA, Ubeda C, Zenewicz LA, et al. Bacterial flagellin stimulates tolllike receptor 5-dependent defense against vancomycin-resistant Enterococcus infection. J Infect Dis 2010; 201:534-543.
52. Franchi L, Kamada N, Nakamura Y, et al. NLRC4-driven production of IL-1beta discriminates between pathogenic and commensal bacteria and promotes host intestinal defense. Nat Immunol 2012; 13:449-456.
53. Satoh-Takayama N, Vosshenrich CA, Lesjean-Pottier S, et al. Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide innate mucosal immune defense. Immunity 2008; 29:958-970.
54. Rea MC, Sit CS, Clayton E, et al. Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile. Proc Natl Acad Sci U S A 2010; 107:9352-9357.
55. Theriot CM, Koenigsknecht MJ, Carlson PE Jr, et al. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat Commun 2014; 5:3114.
56. Ng KM, Ferreyra JA, Higginbottom SK, et al. Microbiota-liberated host sugars facilitate postantibiotic expansion of enteric pathogens. Nature 2013; 502:96-99.
57. Committee On Infectious Diseases, American Academy of Pediatrics. Schutze GE, Willoughby RE. Clostridium difficile infection in infants and children. Pediatrics 2013; 131:196-200.